Edition:
United States

Achillion Pharmaceuticals Inc (ACHN.OQ)

ACHN.OQ on NASDAQ Stock Exchange Global Select Market

3.45USD
20 Nov 2017
Change (% chg)

-- (--)
Prev Close
$3.45
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
422,749
52-wk High
$5.66
52-wk Low
$2.95

Select another date:

Wed, Nov 15 2017

BRIEF-Achillion announces pricing of secondary offering of common stock

* Achillion announces pricing of secondary offering of common stock

BRIEF-Achillion announces proposed secondary offering of common stock

* Achillion announces proposed secondary offering of common stock

BRIEF-Achillion reports preliminary proof-of-concept with ACH-4471 for the treatment of c3g

* Achillion reports preliminary proof-of-concept with ACH-4471 for the treatment of c3g

BRIEF-Achillion says ACH-4471 granted orphan drug designation by FDA

* Achillion announces ACH-4471 granted orphan drug designation by the FDA and positive opinion for orphan drug designation in the european union for the treatment of paroxysmal nocturnal hemoglobinuria

BRIEF-Achillion Q3 loss per share $0.14

* Achillion reports third quarter 2017 financial results and provides update on clinical programs

BRIEF-RTW Investments reports 5.2 pct passive stake in Achillion Pharmaceuticals - SEC filing‍​

* RTW Investments LP reports 5.2 percent passive stake in Achillion Pharmaceuticals Inc as of September 18, 2017 - SEC filing‍​ Source text: (http://bit.ly/2wXrbF8) Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

BRIEF-Achillion announces termination of worldwide collaboration for hepatitis c with Janssen

* Achillion announces termination of worldwide collaboration for hepatitis c with Janssen Further company coverage:

BRIEF-Achillion Pharmaceuticals says Joel Barrish plans to leave co

* Achillion Pharmaceuticals Inc - ‍announced that Joel Barrish, executive vice president and chief scientific officer, plans to leave company

Select another date: